Compare D R Horton Inc (DHI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? D R Horton Inc trades at $150.79 (market cap $42.18B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.2× D R Horton Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DHI | VRTX | |
|---|---|---|
Market Cap | $42.18B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $529.65 |
52-Week Low | $132.53 | $376.62 |
Enterprise Value | $47.28B | $128.37B |
Dividend Yield | 1.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
